152 related articles for article (PubMed ID: 37226927)
1. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
[TBL] [Abstract][Full Text] [Related]
2. The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Dand N; Barker JN; Smith CH; Griffiths CEM;
Br J Dermatol; 2024 Apr; 190(5):689-700. PubMed ID: 38051972
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Alabas OA; Mason KJ; Yiu ZZN; Hampton PJ; Reynolds NJ; Owen CM; Bewley A; Laws PM; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Apr; 188(5):618-627. PubMed ID: 36763783
[TBL] [Abstract][Full Text] [Related]
4. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
6. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
[TBL] [Abstract][Full Text] [Related]
7. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
[TBL] [Abstract][Full Text] [Related]
8. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
[TBL] [Abstract][Full Text] [Related]
9. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
10. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
Zidane M; Dressler C; Gaskins M; Nast A
JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
[TBL] [Abstract][Full Text] [Related]
11. Real-world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis.
Svedbom A; Ståhle M
J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):525-532. PubMed ID: 31568598
[TBL] [Abstract][Full Text] [Related]
12. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
13. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
[TBL] [Abstract][Full Text] [Related]
15. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.
Reich K; Signorovitch J; Ramakrishnan K; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
J Am Acad Dermatol; 2010 Dec; 63(6):1011-8. PubMed ID: 20933301
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study.
Li G; Gu Y; Zou Q; Wang Y; Xiao Y; Xia D; Zhan T; Zhou X; Wang Q; Yan W; Li W
Dermatol Ther (Heidelb); 2022 Sep; 12(9):2105-2115. PubMed ID: 35953612
[TBL] [Abstract][Full Text] [Related]
17. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
[TBL] [Abstract][Full Text] [Related]
18. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
19. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
[TBL] [Abstract][Full Text] [Related]
20. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]